This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories (ABT): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Abbott Laboratories ( ABT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Abbott Laboratories rose $1.14 (1.8%) to $64.47 on light volume. Throughout the day, 2.8 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.3 million shares. The stock ranged in a price between $63.44-$64.49 after having opened the day at $63.48 as compared to the previous trading day's close of $63.33. Other companies within the Drugs industry that increased today were: MAP Pharmaceuticals ( MAPP), up 20.3%, Star Scientific ( STSI), up 13.6%, Rosetta Genomics ( ROSG), up 12.9%, and Coronado Biosciences ( CNDO), up 12.6%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $100.1 billion and is part of the health care sector. The company has a P/E ratio of 15.5, below the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Dynavax Technologies Corporation ( DVAX), down 5.5%, Telik ( TELK), down 4.8%, Biocryst Pharmaceuticals ( BCRX), down 4.7%, and Biostar Pharmaceuticals ( BSPM), down 4.7%, were all laggards within the drugs industry with Vivus ( VVUS) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs